Navigation Links
Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Date:9/4/2008

BEDFORD, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) today announced that Glenn Muir, Chief Financial Officer, will be presenting at the Morgan Stanley Global Healthcare Unplugged Conference being held September 9, 2008, at the Grand Hyatt Hotel in New York, NY.

Interested parties are invited to listen to a live audio webcast of Hologic's investor presentation on Tuesday, September 9, 2008, at 1:35 PM., Eastern Time on the investor section of the Company's website at http://www.hologic.com/investor . An archive of the presentation will be available for replay following the conference.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic leads the industry in digital mammography systems and offers the most advanced technology for breast imaging and breast biopsy. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging. For more information visit http://www.hologic.com .

Contact: Deborah Gordon Frances Doria

Vice President, Investor Relations Director, Investor Relations

Hologic, Inc. Hologi
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
2. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
3. Hologic to Present at the Needham Seventh Annual Biotechnology and Medical Technology Conference
4. Hologic to Present at the Citigroup Investment Research Global Healthcare Conference
5. Hologic to Present at the Bank of America Healthcare Conference
6. Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens
7. Hologic to Present at the Sun Trust Robinson Humphreys 37th Annual Institutional Conference
8. Hologic Announces First Quarter Fiscal 2008 Operating Results
9. Hologic to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens
11. Insmed to Present at BioPharm Asia 2008 Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., LIBREVILLE, Gabon, December 2 /PRNewswire/ -... Everyone,s Problem and Heritage" , Coinc... 2-3 June 2010 the,Gabonese Republic is hosting an... the issue of safeguarding biological resources in...ment and state leaders, ministers,scientific expe...
(Date:12/2/2009)... , CAMBRIDGE, Mass., Dec. 2 Te...aders in technology development and product integr...nounced the December 11th deadline for technology ... its 14th year, TechConnect World, in association ...TI), and the Clean Technology and Sustainable Indu...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte...el oral JAK2 inhibitor, SB1518, at The American So...tion in New Orleans. ,, Data will be presented ...lation trial of SB1518 detailing its safety, toler...) profile in dose levels ranging from 100 to 600 m...
(Date:12/2/2009)..., NANJING, China, Dec. 2 /PRNewswire-Asia/ -...Company") (NYSE: SCR ), a leading pharmaceutical...uring, and marketing of branded,generic and propri...at 105 of,its drugs have been included in China,s ...as issued by China,s Ministry of Human Resources a...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
..., R.I., May 28 Neurotech Pharmaceuticals, Inc. to..., NT-501, demonstrated a strong biologic effect ...ntosa (RP). RP is a slowly developing condition ...mp; cone photoreceptor cells in the retina that ov... eventually leads to blindness. RP is an orphan-de...
...NS, France, May 28 Poxel is a research integrated...ck Serono a division of,Merck KGaA, Germany, follo...est in diabetes research and development. It aims ...iseases (with a primary focus on Type 2,diabetes) ..., before,out-licensing these projects to major pha...
...rovides way of integrating and sustaining positive...28 In today,s uncertain times, increased stress c...rging wellness, growth and behavioral change parad...make healthier lifestyle choices and enjoy increas...llenges. , , The approach, called Reorganizationa...
Other Biology Technology:Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 2Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 3Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 4Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors 5Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management 2Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress 2
(Date:12/3/2009)...ies can be likened to emptying a museum of its col...dicines into the trash, or replacing every local c...e of species and their habitats may not just make ... also put you at greater risk for catching some na...sity loss,"driven by the replacement of local spec...
(Date:12/3/2009)... CTRC-AACR San Antonio Breast Cancer Symposium con...e and world leaders from industry and academia wit... year, more than 8,500 scientists and other profes...ntion Center in San Antonio from Dec. 9-13, 2009. ...n Association for Cancer Research, the University ...
(Date:12/3/2009)...ty change in warmer water, according to an intrigu...ake some species more aggressive. , Experiments ...s Great Barrier Reef have shown for the first time..., or consistently bold, and that these individual ...ures rise. , A slight lift of just one or two de...
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Fish with attitude: Some like it hot 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 1LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 2LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 3LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 4LIVALO 28R 29 Demonstrates Sustained Long Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 55843 5Growth Attracts Additional Investors to Sittercity com 55841 1Growth Attracts Additional Investors to Sittercity com 55841 2iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 1iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 2
...tin has received a six-year contract from the U.S....rt for the AN/UYQ-70 (Q-70) Advanced Display Syste... support at over $13 million a year for the first ...r the next four years, bringing the total potentia...t follows a recently awarded $525.6 million modifi...
...s March 19 during 12 p.m. Advertising Research Fou...e Research (R), a revolutionary media research fir... Advertising Research Foundation (ARF) conference ...identified key themes and styles that comprise imp...which were captured and delivered during the ARF,s...
...niversity of Florida have introduced ,Delicious, a...early, produces high yields, and is disease-resist...d texture with an edible skin, making it well-suit...or wine production. The name ,Delicious, was selec... sampled the fruit., According to Dr. Dennis J. Gr...
Other Biology News:U.S. Navy Awards Lockheed Martin Six-year Contract Worth Up to $72 Million for Advanced Display Systems Support 2Innerscope Research(R) Uses Same-Day Results From Biometric Study to Identify Key Themes, Styles Behind Effective, Engaging Speaker Presentations 2
Mouse Anti-Human QPRT Monoclonal Antibody, Unconjugated, Clone 5D11 from ABR-Affinity BioReagents
ZOOM IPGRunner Mini-cell from Invitrogen
Rabbit Anti-XTP4 Polyclonal Antibody, Unconjugated from Abcam
Agarose, Type C from Calbiochem
Biology Products: